Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080054 · ClinicalTrials.gov registry record · Phase 1
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00080054: Completed Phase 1 study, sponsored by Pharmacyclics.
NCT00080054 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00080054, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to find out about the safety of adding the investigational drug motexafin gadolinium to a standard course of chemotherapy with temozolomide for patients with malignant glioma. Secondly, the study will determine how many patients will respond to this treatment.
Interventions
- DRUG Motexafin Gadolinium Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Phase | Phase 1 |
What the finished NCT00080054 record still lists
NCT00080054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which Motexafin Gadolinium Injection is the first listed.
NCT00080054 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00080054 about?
NCT00080054 is a clinical study titled "A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas". The purpose of this study is to find out about the safety of adding the investigational drug motexafin gadolinium to a standard course of chemotherapy with temozolomide for patients with malignant glioma. Secondly, the study will determine how many patients will respond to this treatment.
What is the current status of trial NCT00080054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants.
What interventions are being tested in trial NCT00080054?
The interventions under investigation include: Motexafin Gadolinium Injection (DRUG).
Who is sponsoring clinical trial NCT00080054?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00080054's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant